DICE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

DI

Volume

2.20K

Loading chart

DI

DICETema Trading & Prediction Markets ETF

DICE

Pay with—

Available Balance0.00

DI

AUM

N/A

Volume

2.20K

Yield

N/A

Chart Earnings News About Insider Filings

What 9 Analyst Ratings Have To Say About DICE TherapeuticsAnalysts have provided the following ratings for DICE Therapeutics (NASDAQ:DICE) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 7 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 5 0 0 3M Ago 2 0 1 0 0 These 9 analysts have an average price target of $50.78 versus the current price of DICE Therapeutics at $47.55, implying upside. Below is a summary of how these 9 analysts rated DICE Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the ...Full story available on Benzinga.comBenzinga · Aug 9, 2023

Eli Lilly (LLY) Q2 Earnings Beat, Mounjaro Powers Sales GrowthEli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its financial guidance for 2023.Zacks Investment Research · Aug 8, 2023

Top 5 Health Care Stocks That May Crash In Q3The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. TC Biopharm (Holdings) Plc (NASDAQ: TCBP) TC BioPharm regained compliance with the Nasdaq Stock Market Listing Rule 5550(b) which will maintain the listing ...Benzinga · Aug 7, 2023

Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Eli Lilly's (LLY) second-quarter sales.Zacks Investment Research · Aug 2, 2023

Why Shares of Ventyx Biosciences Rose MondayThe company has several promising autoimmune therapies.The Motley Fool · Jul 3, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023Upgrades According to B. Riley Securities, the prior rating for Identiv Inc (NASDAQ:INVE) was changed from Neutral to Buy. Identiv earned $0.13 in the first quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $16.92 and a 52-week-low of $5.07. Identiv closed at $7.18 at the end of the last trading period. For Century Communities Inc (NYSE:CCS), B. Riley Securities upgraded the previous rating of Neutral to Buy. In the first quarter, Century Communities showed an EPS of $1.04, compared to $4.20 from the year-ago quarter. At the moment, the stock has a 52-week-high of $72.08 and a 52-week-low of $40.40. Century Communities closed at $71.05 at the end of the last trading period. According to Loop Capital, the prior rating for Weave Communications Inc (NYSE:WEAV) was changed from Hold to Buy. For the first quarter, Weave Communications had an EPS of $0.05, compared to year-ago quarter EPS of $0.16. At the moment, the stock has a 52-week-high of $9.13 and a 52-week-low of $2.99. Weave Communications closed at $9.13 at the end of the last trading period. According to DA Davidson, the prior rating for WSFS Financial Corp (NASDAQ:WSFS) was changed from Neutral to Buy. In the first quarter, WSFS Financial showed an EPS of $1.02, compared to $0.66 from the year-ago quarter. The stock has a 52-week-high of $51.77 and a 52-week-low of $29.59. At the end of the last trading period, WSFS Financial closed at $35.17. For Burlington Stores Inc (NYSE:BURL), Gordon Haskett upgraded the previous rating of Accumulate to Buy. Burlington Stores earned $0.84 in the first quarter, compared to $0.54 in the year-ago quarter. The current stock performance of Burlington Stores shows a 52-week-high of $239.94 and a 52-week-low of $106.81. Moreover, at the end of the last trading period, the closing price was at $157.98. According to B of A Securities, the prior rating for Alliant Energy Corp (NASDAQ:LNT) was changed from Neutral to Buy. Alliant Energy earned $0.65 in the first quarter, compared to $0.77 in the year-ago quarter. The stock has a 52-week-high of $64.59 and a 52-week-low of $47.23. At the end of the last trading period, Alliant Energy closed at $51.83. For Sherwin-Williams Co (NYSE:SHW), BMO Capital upgraded the previous rating of Market Perform to Outperform. For the first quarter, Sherwin-Williams had an EPS of $2.04, compared to year-ago quarter EPS of $1.61. The stock has a 52-week-high of $264.69 and a 52-week-low of $195.57. At the end of the last trading period, Sherwin-Williams closed at $247.04. According to UBS, the prior rating for Moderna Inc (NASDAQ:MRNA) was changed from Neutral to Buy. For the first quarter, Moderna had an EPS of $0.19, compared to year-ago quarter EPS of $8.58. The current stock performance of Moderna shows a 52-week-high of $217.20 and a 52-week-low of $115.06. Moreover, at the end of the last trading period, the closing price was at $118.50. Keybanc upgraded the previous rating for Sotera Health Co (NASDAQ:SHC) from Sector Weight to Overweight. For the first quarter, Sotera Health had an EPS of $0.13, compared to year-ago quarter EPS of $0.22. At the moment, the stock has a 52-week-high of $20.95 and a 52-week-low of $5.78. Sotera Health closed at $17.99 at the end of the last trading period. See all analyst ratings upgrades. Downgrades According to Raymond James, the prior rating for FibroGen Inc (NASDAQ:FGEN) was changed from Outperform to Market Perform. FibroGen earned $0.81 in the first quarter, compared to $0.68 in the year-ago quarter. The stock has a 52-week-high of $25.69 and a 52-week-low of $10.46. At the end of the last trading period, FibroGen closed at $16.05. For FibroGen Inc (NASDAQ:FGEN), William Blair downgraded the previous rating of Outperform to Market Perform. For the first quarter, FibroGen had an EPS of $0.81, compared to ...Full story available on Benzinga.comBenzinga · Jun 26, 2023

Why Dice Therapeutics Stock Bolted Higher This WeekThe small-cap drugmaker fetched a hefty premium in a buyout deal with Eli Lilly.The Motley Fool · Jun 22, 2023

Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & MoreAcquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.Zacks Investment Research · Jun 22, 2023

DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli LillyDICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.Zacks Investment Research · Jun 21, 2023

ETFs to Capitalize on Eli Lilly's Buyout of DICE TherapeuticsEli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, specifically targeting immune disease-related treatments.Zacks Investment Research · Jun 21, 2023

to start trading

DI

DICETema Trading & Prediction Markets ETF

DICE

Pay with—

Available Balance0.00

Your PositionYou don't own any DICE yet.

Related Tickers

Earnings